Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Radiation Oncology
Does the extent of ENE affect your recommendation for concurrent chemotherapy in HPV+ OPSCC patients planned for adjuvant RT?
Does the ENE of 1 mm or less versus >1 mm as in ECOG 3311 affect your decision?
Answer from: Radiation Oncologist at Academic Institution
I'm wary of de-escalating treatment without phase 3 data supporting that decision. So any ECE, I treat with 66 Gy and concurrent chemo.
Sign in or Register to read more
19938
Related Questions
What are your top takeaways in Head & Neck Cancers from ASCO 2025?
Would you recommend adjuvant radiation for a patient with head/neck merkel cell carcinoma following a pathologic complete response to neoadjuvant immunotherapy?
What is the recommended adjuvant dose for neuroendocrine cancer in the head and neck?
How do you counsel patients regarding alcohol consumption following treatment of head and neck cancer?
How should you approach treating curable laryngeal cancer with chemo-RT in a patient who had a myocardial infarction during treatment and requires CABG, given the cardiotoxicity of cisplatin and 5FU/carboplatin?
How do you treat SNUC?
How would you approach a patient with a carotid body tumor and metastasis to the cervical lymph node?
What alternatives do you recommend for oral dexamethasone solution for HN cancer?
Is there a role for reirradiation for SCC oral tongue with high-risk features (i.e., PNI, close margins) following surgery?
When would you consider larynx preservation in patients with T4N+ SCC of the larynx?